Drugs.com - Monthly Update June 2025
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
Drugs.com - Monthly Update June 2025
-
Narrated by:
-
By:
About this listen
This is the June 2025 edition of the Drugs.com Monthly Update. We cover five significant FDA approvals that are transforming patient care across multiple therapeutic areas.
- Dupixent (dupilumab), newly approved for treating bullous pemphigoid in adults—a painful autoimmune skin disorder primarily affecting patients over 65.
- Mavyret (glecaprevir/pibrentasvir) for acute hepatitis C virus treatment in children as young as 3 years old.
- Yeztugo (lenacapavir), a groundbreaking twice-yearly injectable HIV prevention therapy offering a 99.9% effectiveness rate in clinical trials.
- Enflonsia (clesrovimab-cfor), a new RSV prevention option for neonates and infants that provides season-long protection with a single injection.
- Ibtrozi (taletrectinib), an oral targeted therapy approved for ROS1-positive non-small cell lung cancer in patients with locally advanced or metastatic disease.
Chapters:
- (00:00) - Intro
- (00:24) - Overview
- (00:45) - Dupixent
- (01:38) - Mavyret
- (02:14) - Yeztugo
- (03:14) - Enflonsia
- (03:54) - Ibtrozi
- (04:26) - Outro
Follow Drugs.com:
- X, Facebook, Youtube
- Signup to our newsletters
- Download the app
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.